Navigation Links
Early Stage Drug Delivery Technologies: 62 Profiles of Start-ups and Emerging Companies

DUBLIN, April 30, 2013 /PRNewswire/ --

Research and Markets has announced the addition of the "Early Stage Drug Delivery Technologies: Profiles of Start-ups and Emerging Companies" report to their offering.


The report focuses on start-ups and smaller companies that tend to be less well known, but are expected to gain momentum as they advance their technologies and produce significant clinical data. All of the companies profiled have interest in forming new partnerships or receiving funding to enable further development and eventual commercialization of their technologies.

The report features profiles of 62 companies, a majority of which were founded in the past five years. Most are located in the United States; however a few profiled companies are based in Canada, Europe, and Australia. Approximately 50% of the companies are affiliated with a University, and ten companies have initiated human clinical trials.

Collectively, the emerging companies profiled in this report are focused on 11 different therapeutic categories. Oncology is the leading focus among companies investigated, and approximately 25 percent of the companies profiled are developing proprietary technologies designed to improve delivery of macromolecules/biologics. Another 25 percent of the companies are focused on novel delivery devices, ranging from inhalation and nasal devices, to more patient-friendly injectable systems. All of the companies investigated are developing technologies that could potentially transform drug delivery in one or more therapeutic areas.

For each company profiled, the following information is provided:

  • Detailed Technology Description
  • Development Status / Pipeline Products
  • Patents and Publications
  • Partnership and Funding Opportunities
  • Business Development & Licensing Contact

Examples of Technologies Presented

  • Mini-pump for subcutaneous delivery of IV medications
  • Targeted nanoparticle micelles
  • Antibody-targeted liposomes
  • Abuse-deterrent delivery system
  • Dry powder particle processing technology
  • Oral capsule technology for biologics
  • Nanovesicle delivery system for delivery across the blood-brain barrier
  • Timed-release intra-ocular implant device
  • Non-invasive aerosol device for brain drug delivery
  • Extracellular drug conjugate technology
  • Nanoparticles and novel device for CNS and inner ear drug delivery
  • Next-generation auto-injector technology
  • Nanopolymer drug conjugates
  • Microneedle patch system
  • Pocket-sized ultrasound delivery device
  • Biodegradable, topical drug patch

62 Company Profiles (partial listing)

  • Affinity Therapeutics
  • Aquarius Biotechnologies
  • Axxia Pharmaceuticals
  • Blend Therapeutics
  • Clearside Biomedical
  • Cristal Delivery BV
  • DLVR Therapeutics
  • EnduRx Pharmaceuticals
  • Ekteino Laboratories
  • Extend Biosciences
  • Inspiro Medical
  • KAER Biotherapeutics
  • Lauren Sciences, LLC
  • LyoGo LLC
  • Orbis Biosciences
  • ProLynx LLC
  • Prometheon Pharma, LLC
  • Qrono, Inc.
  • scPharmaceuticals, LLC
  • Vaxxas

+ 42 More Companies

Reasons to Buy

- Identify early stage delivery technologies that will potentially enable the delivery of your therapeutic compound
- Learn about investment opportunities with emerging companies, to gain access to promising, early stage technologies
- Identify novel drug delivery formulations available for partnering, to enhance your product portfolio

For more information visit Early Stage Drug Delivery Technologies: Profiles of Start-ups and Emerging Companies

Research and Markets
Laura Wood , Senior Manager.
U.S. Fax: +1-646-607-1907
Fax (outside U.S.): +353-1-481-1716

SOURCE Research and Markets
Copyright©2012 PR Newswire.
All rights reserved

Related biology technology :

1. Netsmart Clients to Receive Nearly $2 Million in Meaningful Use EHR Incentive Payments
2. Access BridgeGap Ventures to Focus on Early-Stage Therapeutic Opportunities
3. VisionGate Uses $2.6 Million NIH Grant to Achieve Full Automation of Cell-CTâ„¢ 3D Imaging System for Early Diagnosis of Cancer
4. Sequenom Announces 2011 Operational Highlights and Early 2012 Outlook
5. CSL Behring Study Confirms Early Treatment with Berinert® Provides Faster Resolution of Acute Hereditary Angioedema Symptoms
6. Corporate Venturing and Early-Stage Financing in the Spotlight at BioTrinity
7. Butamax Early Adopters Group surpasses capacity targets with addition of Big River; Membership represents 11 production facilities and nearly 900 million gallons of ethanol capacity
8. Researchers peek at the early evolution of sex chromosomes
9. Discuss Early Results of the DIAN Trial at CBIs 6th Annual Alzheimers Drug Development Summit
10. Early career distinction: Prestigious award recognizes physicists work in electron dynamics
11. JCI early table of contents for Sept. 4, 2012
Post Your Comments:
(Date:11/25/2015)... 2015 /PRNewswire/ - Aeterna Zentaris Inc. (NASDAQ:  AEZS; TSX: ... prospects remain fundamentally strong and highlights the following ... received DSMB recommendation to continue the ZoptEC Phase ... the final interim efficacy and safety data ... men with heavily pretreated castration- and Taxane-resistant prostate ...
(Date:11/25/2015)... ... November 25, 2015 , ... Jessica Richman and ... early in their initial angel funding process. Now, they are paying it forward ... make early stage investments in the microbiome space. In this, they join ...
(Date:11/24/2015)... , Nov. 24, 2015 Halozyme Therapeutics, Inc. (NASDAQ: ... Conference in New York on Wednesday, December ... Helen Torley , president and CEO, will provide a corporate overview. ... New York at 1:00 p.m. ET/10:00 a.m. PT . ... investor relations, will provide a corporate overview. --> th ...
(Date:11/24/2015)... 24, 2015 /PRNewswire/ - Aeterna Zentaris Inc. (NASDAQ:  AEZS) (TSX: ... behalf of the Toronto Stock Exchange, confirms that as ... no corporate developments that would cause the recent movements ... --> About Aeterna Zentaris Inc. ... --> Aeterna Zentaris is a specialty biopharmaceutical company ...
Breaking Biology Technology:
(Date:11/10/2015)... 10, 2015 About signature ... helps to identify and verify the identity of ... as the secure and accurate method of authentication ... particular individual because each individual,s signature is highly ... when dynamic signature of an individual is compared ...
(Date:10/29/2015)... 2015   MedNet Solutions , an innovative SaaS-based ... clinical research, is pleased to announce that it has ... as one of only three finalists for a ... and Growing" category. The Tekne Awards honor Minnesota ... technology innovation and leadership. iMedNet™ eClinical ...
(Date:10/29/2015)... Connecticut , October 29, 2015 ... a biometric authentication company focused on the growing ... smart wallet announces that StackCommerce, a leading marketplace ... be featuring the Wocket® smart wallet on StackSocial ... NXTD ) ("NXT-ID" or the "Company"), a biometric ...
Breaking Biology News(10 mins):